Cargando…
Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment
Background: Melphalan was poorly available in mainland China. The aim of this study is to explore the dose-adjusted busulfan/cyclophosphamide (BU/CY) as an alternative regimen in auto stem cell transplantation (ASCT) for multiple myeloma (MM). Methods: A total of 105 newly diagnosed MM patients unde...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573400/ https://www.ncbi.nlm.nih.gov/pubmed/37834886 http://dx.doi.org/10.3390/jcm12196239 |
_version_ | 1785120453874941952 |
---|---|
author | Zhou, Shiyuan Zhai, Yingying Yan, Lingzhi Shi, Xiaolan Shang, Jingjing Wu, Depei Fu, Chengcheng Jin, Song |
author_facet | Zhou, Shiyuan Zhai, Yingying Yan, Lingzhi Shi, Xiaolan Shang, Jingjing Wu, Depei Fu, Chengcheng Jin, Song |
author_sort | Zhou, Shiyuan |
collection | PubMed |
description | Background: Melphalan was poorly available in mainland China. The aim of this study is to explore the dose-adjusted busulfan/cyclophosphamide (BU/CY) as an alternative regimen in auto stem cell transplantation (ASCT) for multiple myeloma (MM). Methods: A total of 105 newly diagnosed MM patients undergoing ASCT during May 2012 and August 2017 were retrospectively analyzed. The BU/CY regimen was applied to 64 patients. Busulfan (9.6 mg/kg or 8.0 mg/kg in total) and cyclophosphamide (3.6 g/m(2) or 3.0 g/m(2) in total) were administered according to the creatinine clearance rate (CCR). A high-dose melphalan (HDMEL) regimen (200 mg/m(2)) was given to the other 41 patients. Results: At a median follow-up of 65 (1~119) months, estimated overall survival (OS) and progression-free survival (PFS) at 104 months in the BU/CY and HDMEL groups were 35.6% vs. 20.5% (p = 0.263) and 20.2% vs. 2.4% (p = 0.035), respectively. The median overall survival (OS) and PFS of the HDMEL and BU/CY groups were 55 vs. 70.5 months and 26 vs. 46.5 months, respectively. In multivariate analysis, the BU/CY regimen was found to be the only protective factor for PFS. No lethal toxicity was found in the BU/CY group, and treatment-related mortality (TRM) in 100 days was similar to the HDMEL group. Conclusions: MM patients may also benefit from the dose-adjusted BU/CY regimen. |
format | Online Article Text |
id | pubmed-10573400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105734002023-10-14 Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment Zhou, Shiyuan Zhai, Yingying Yan, Lingzhi Shi, Xiaolan Shang, Jingjing Wu, Depei Fu, Chengcheng Jin, Song J Clin Med Article Background: Melphalan was poorly available in mainland China. The aim of this study is to explore the dose-adjusted busulfan/cyclophosphamide (BU/CY) as an alternative regimen in auto stem cell transplantation (ASCT) for multiple myeloma (MM). Methods: A total of 105 newly diagnosed MM patients undergoing ASCT during May 2012 and August 2017 were retrospectively analyzed. The BU/CY regimen was applied to 64 patients. Busulfan (9.6 mg/kg or 8.0 mg/kg in total) and cyclophosphamide (3.6 g/m(2) or 3.0 g/m(2) in total) were administered according to the creatinine clearance rate (CCR). A high-dose melphalan (HDMEL) regimen (200 mg/m(2)) was given to the other 41 patients. Results: At a median follow-up of 65 (1~119) months, estimated overall survival (OS) and progression-free survival (PFS) at 104 months in the BU/CY and HDMEL groups were 35.6% vs. 20.5% (p = 0.263) and 20.2% vs. 2.4% (p = 0.035), respectively. The median overall survival (OS) and PFS of the HDMEL and BU/CY groups were 55 vs. 70.5 months and 26 vs. 46.5 months, respectively. In multivariate analysis, the BU/CY regimen was found to be the only protective factor for PFS. No lethal toxicity was found in the BU/CY group, and treatment-related mortality (TRM) in 100 days was similar to the HDMEL group. Conclusions: MM patients may also benefit from the dose-adjusted BU/CY regimen. MDPI 2023-09-27 /pmc/articles/PMC10573400/ /pubmed/37834886 http://dx.doi.org/10.3390/jcm12196239 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zhou, Shiyuan Zhai, Yingying Yan, Lingzhi Shi, Xiaolan Shang, Jingjing Wu, Depei Fu, Chengcheng Jin, Song Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment |
title | Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment |
title_full | Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment |
title_fullStr | Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment |
title_full_unstemmed | Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment |
title_short | Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment |
title_sort | busulfan/cyclophosphamide compared with melphalan as a conditioning regimen for autologous transplantation of multiple myeloma: a long-term assessment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573400/ https://www.ncbi.nlm.nih.gov/pubmed/37834886 http://dx.doi.org/10.3390/jcm12196239 |
work_keys_str_mv | AT zhoushiyuan busulfancyclophosphamidecomparedwithmelphalanasaconditioningregimenforautologoustransplantationofmultiplemyelomaalongtermassessment AT zhaiyingying busulfancyclophosphamidecomparedwithmelphalanasaconditioningregimenforautologoustransplantationofmultiplemyelomaalongtermassessment AT yanlingzhi busulfancyclophosphamidecomparedwithmelphalanasaconditioningregimenforautologoustransplantationofmultiplemyelomaalongtermassessment AT shixiaolan busulfancyclophosphamidecomparedwithmelphalanasaconditioningregimenforautologoustransplantationofmultiplemyelomaalongtermassessment AT shangjingjing busulfancyclophosphamidecomparedwithmelphalanasaconditioningregimenforautologoustransplantationofmultiplemyelomaalongtermassessment AT wudepei busulfancyclophosphamidecomparedwithmelphalanasaconditioningregimenforautologoustransplantationofmultiplemyelomaalongtermassessment AT fuchengcheng busulfancyclophosphamidecomparedwithmelphalanasaconditioningregimenforautologoustransplantationofmultiplemyelomaalongtermassessment AT jinsong busulfancyclophosphamidecomparedwithmelphalanasaconditioningregimenforautologoustransplantationofmultiplemyelomaalongtermassessment |